Craneware plc (LON:CRW - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,780 and traded as low as GBX 1,518. Craneware shares last traded at GBX 1,520, with a volume of 513,065 shares traded.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Berenberg Bank reiterated a "buy" rating and issued a GBX 2,900 price target on shares of Craneware in a research note on Tuesday, January 20th. Shore Capital Group reiterated a "buy" rating and issued a GBX 2,850 price target on shares of Craneware in a research note on Tuesday, January 20th. Finally, UBS Group reiterated a "buy" rating and issued a GBX 570 price target on shares of Craneware in a research note on Wednesday, March 25th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Craneware presently has an average rating of "Buy" and a consensus price target of GBX 2,297.75.
View Our Latest Research Report on Craneware
Craneware Stock Down 0.3%
The company has a current ratio of 0.76, a quick ratio of 1.00 and a debt-to-equity ratio of 7.93. The firm's 50 day simple moving average is GBX 1,433.82 and its 200-day simple moving average is GBX 1,780. The stock has a market capitalization of £533.23 million, a price-to-earnings ratio of 24.17 and a beta of 0.28.
Craneware Company Profile
(
Get Free Report)
For over 25 years, The Craneware Group AIM: CRW.L has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster - that simplify the complexities of healthcare finance and operations.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Craneware, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Craneware wasn't on the list.
While Craneware currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.